News

Erisyon, a biotechnology company specializing in the study of proteins, was awarded a grant by The Michael J. Fox Foundation (MJFF) to find and validate potential markers of Parkinson’s disease in its early stages. The grant, reported to be worth $189,000, will go toward deploying single-molecule protein sequencing to detect and…

Parkinson Canada is inviting patients to join the Canadian Open Parkinson Network (C-OPN) to help advance Parkinson’s disease care and research. The national research platform seeks to drive more efficient research, accelerate disease understanding, and uncover new treatments for the neurodegenerative disorder. The hope is to facilitate rapid…

Structural changes within alpha-synuclein can make this protein more prone to clumping — a common feature of Parkinson’s — a research group found, a discovery that might lead to ways of stopping this disease in its early stages. The study, “Extent of N-terminus exposure of monomeric alpha-synuclein…

Kynmobi (apomorphine hydrochloride) soluble film has been approved by Health Canada as an on-demand treatment for off episodes in people with Parkinson’s disease, its developer Sunovion, announced. Sunovion…

A miniature, wireless, and magnetically powered neural stimulator may be the future of deep brain stimulation for Parkinson’s disease, and disorders like epilepsy and chronic pain, a study reported.  The study, “Magnetoelectric Materials for Miniature, Wireless…

In his new role as Michael J. Fox Foundation (MJFF) ambassador, sports channel ESPN founder Bill Rasmussen will focus on involving newly diagnosed Parkinson’s patients in clinical trials. Diagnosed with Parkinson’s in 2014 at age 81, Rasmussen also will sit on the…

Acadia Pharmaceuticals announced it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for a new indication for Nuplazid (pimavanserin) in the treatment of hallucinations and delusions associated with dementia-related psychosis. Dementia affects approximately 8 million people in the U.S. and is…

Supernus Pharmaceuticals’ acquisition of US WorldMeds’ portfolio of central nervous system (CNS) disease treatments adds two established Parkinson’s disease (PD) therapies and a leading investigative product to its neurology portfolio. The deal calls for a $300 million upfront cash outlay, plus $230 million in milestone payments for…

A Phase 1/2 clinical trial testing AXO-Lenti-PD (OXB102), Axovant‘s experimental gene therapy for Parkinson’s disease, has completed dosing of all four adults in a second group in its dose-escalation part of the study. Six-month data on these patients is expected by year’s end. AXO-Lenti-PD is a one-time gene therapy…

Current Parkinson’s treatments are insufficient for people with late-stage disease, inadequately controlling for many notable motor and non-motor symptoms, a study in these patients across Europe reports. The study, “The late stage of Parkinson’s — results of a large multinational study on motor and non-motor complications,” was…